文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

淋巴结清扫不足的结直肠癌患者基于阳性淋巴结的分期系统的对数比值:辅助化疗的潜在参考

Log odds of positive lymph nodes-based staging system for colorectal cancer patients with inadequate lymph nodes harvested: a potential reference for adjuvant chemotherapy.

作者信息

Wang Hongwei, Wang Linlin, Li Zhong, Zhang Jiahang, Liu Guohui

机构信息

Department of General Surgery, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.

Department of Neurology, Heilongjiang Hospital, Beijing Children's Hospital, Harbin, China.

出版信息

J Gastrointest Oncol. 2025 Jun 30;16(3):1038-1049. doi: 10.21037/jgo-2024-910. Epub 2025 Jun 16.


DOI:10.21037/jgo-2024-910
PMID:40672087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12260946/
Abstract

BACKGROUND: The current tumor node metastasis (TNM) staging manual of the American Joint Committee on Cancer (AJCC) could not satisfactorily classify colorectal cancer (CRC) patients with lymph node examined (LNE) <12. This study aims to construct a novel staging system for better predicting cancer-specific survival (CSS) in this special population. METHODS: Medical records of 4,170 CRC patients were retrospectively reviewed, including 3,927 cases from the Surveillance, Epidemiology, and End Results (SEER) database (development set) and 243 cases from The Second Affiliated Hospital of Harbin Medical University (validation set). Survival analysis was performed using Cox regression model. The best cutoff point of log odds of positive lymph nodes (LODDS) of CSS was calculated through the X-tile software. The performance of novel stage (nStage) was appraised by concordance index (C-index), receiver operating characteristic (ROC) curves and decision curve analyses (DCA). RESULTS: LODDS was an independent prognosticator for CSS and a novel N stage (nN stage) was built subsequently (nN0: LODDS ≤-1.1, nN1: -1.1< LODDS ≤-0.2 or cancer nodule formation and nN2: LODDS >-0.2). The C-indexes in the nStage system were higher and the 5-year ROC curves and DCA showed the superior power of the model compared with the AJCC system. Besides, in nStage C-E but not A-B CRC, patients who were treated with adjuvant chemotherapy posed a better prognosis. CONCLUSIONS: The nStage system demonstrated superiority over the AJCC staging system for CRC patients with LNE <12. And the proposed nStage system might provide clinicians with a potential reference for selecting patients who might benefit from adjuvant chemotherapy.

摘要

背景:美国癌症联合委员会(AJCC)当前的肿瘤淋巴结转移(TNM)分期手册无法令人满意地对检查淋巴结数(LNE)<12的结直肠癌(CRC)患者进行分类。本研究旨在构建一种新的分期系统,以更好地预测这一特殊人群的癌症特异性生存(CSS)。 方法:回顾性分析4170例CRC患者的病历,其中3927例来自监测、流行病学和最终结果(SEER)数据库(开发集),243例来自哈尔滨医科大学附属第二医院(验证集)。采用Cox回归模型进行生存分析。通过X-tile软件计算CSS的阳性淋巴结对数优势比(LODDS)的最佳截断点。通过一致性指数(C-index)、受试者工作特征(ROC)曲线和决策曲线分析(DCA)评估新分期(nStage)的性能。 结果:LODDS是CSS的独立预后因素,随后构建了新的N分期(nN分期)(nN0:LODDS≤-1.1,nN1:-1.1<LODDS≤-0.2或有癌结节形成,nN2:LODDS>-0.2)。与AJCC系统相比,nStage系统的C-index更高,5年ROC曲线和DCA显示该模型具有更强的预测能力。此外,在nStage C-E期而非A-B期的CRC患者中,接受辅助化疗的患者预后更好。 结论:对于LNE<12的CRC患者,nStage系统显示出优于AJCC分期系统的优势。所提出的nStage系统可能为临床医生选择可能从辅助化疗中获益的患者提供潜在参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/f5a1fa37f9d4/jgo-16-03-1038-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/33eccb557391/jgo-16-03-1038-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/ab39ad29c8d0/jgo-16-03-1038-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/22ec88f6df6b/jgo-16-03-1038-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/11671838d6ce/jgo-16-03-1038-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/bc1665f591aa/jgo-16-03-1038-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/892b81634aa5/jgo-16-03-1038-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/f5a1fa37f9d4/jgo-16-03-1038-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/33eccb557391/jgo-16-03-1038-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/ab39ad29c8d0/jgo-16-03-1038-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/22ec88f6df6b/jgo-16-03-1038-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/11671838d6ce/jgo-16-03-1038-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/bc1665f591aa/jgo-16-03-1038-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/892b81634aa5/jgo-16-03-1038-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e17/12260946/f5a1fa37f9d4/jgo-16-03-1038-f7.jpg

相似文献

[1]
Log odds of positive lymph nodes-based staging system for colorectal cancer patients with inadequate lymph nodes harvested: a potential reference for adjuvant chemotherapy.

J Gastrointest Oncol. 2025-6-30

[2]
Competing risk and random survival forest models for predicting survival in post-resection elderly stage I-III colorectal cancer patients.

Sci Rep. 2025-7-7

[3]
Comparison of LNR- and LODDS-based predictive models for prognosis in non-elderly patients with locally advanced rectal cancer undergoing neoadjuvant therapy.

Int J Colorectal Dis. 2025-7-12

[4]
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.

Clin Orthop Relat Res. 2024-12-1

[5]
Development and validation of a prognostic model for overall survival in pN0 esophageal cancer patients after neoadjuvant chemotherapy: a SEER database-based study.

J Thorac Dis. 2025-5-30

[6]
Development and validation of nomograms for predicting survival of locally advanced rectosigmoid junction cancer patients: a SEER database analysis.

Transl Cancer Res. 2025-5-30

[7]
Evaluation of LNR and modified N stage systems for prognostic stratification of metastatic lymph nodes in stage III colorectal Cancer.

Sci Rep. 2025-4-21

[8]
Construction and validation of nomograms for predicting the prognosis of elderly patients with uterine serous carcinoma: a SEER-based study.

J Cancer Res Clin Oncol. 2023-11

[9]
Development and validation of a Log odds of negative lymph nodes/T stage ratio-based prognostic model for gastric cancer.

Front Oncol. 2025-6-3

[10]
A novel risk model for predicting peritoneal metastasis in colorectal cancer based on the SEER database.

J Cancer Res Clin Oncol. 2023-11

本文引用的文献

[1]
Superior prognosis stratification for stage III colon cancer using log odds of positive lymph nodes (LODDS) compared to TNM stage classification: the Japanese study group for postoperative follow-up of colorectal cancer.

Oncotarget. 2020-8-18

[2]
Clinical efficacy of adjuvant chemotherapy in the treatment of pT4 stage II colorectal cancer with defective mismatch repair status: A protocol for systematic review and meta-analysis.

Medicine (Baltimore). 2020-6-26

[3]
Prognosis of colorectal cancer patients is associated with the novel log odds of positive lymph nodes scheme: derivation and external validation.

J Cancer. 2020-1-16

[4]
Colorectal cancer statistics, 2020.

CA Cancer J Clin. 2020-3-5

[5]
Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study.

J Res Med Sci. 2019-5-22

[6]
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2018-7

[7]
NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

J Natl Compr Canc Netw. 2018-4

[8]
What Is the Minimum Number of Examined Lymph Nodes After Neoadjuvant Therapy in Rectal Cancer?

J Gastrointest Surg. 2018-2-21

[9]
Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence.

Gastrointest Tumors. 2017-9

[10]
The survival and clinicopathological differences between patients with stage IIIA and stage II rectal cancer: An analysis of 12,036 patients in the SEER database.

Oncotarget. 2016-11-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索